Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer

Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia

(2013) Andrew M Stein et al.   BMC CANCER

Optimization of personalized therapies for anticancer treatment

(2013) Alexei Vazquez   BMC Systems Biology

Integrating Clinical Pharmacology Concepts in Individualized Therapy With Tyrosine Kinase Inhibitors

(2013) C D Drenberg et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Progress in Structure-Based Design of EGFR Inhibitors

(2013) Petar M. Mitrasinovic   CURRENT DRUG TARGETS

Chronic Myeloid Leukemia: Overview of New Agents and Comparative Analysis

(2013) Preetesh Jain et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Erlotinib in the first-line treatment of non-small-cell lung cancer

(2013) Manolo D’Arcangelo et al.   Expert Review of Anticancer Therapy

Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial

(2013) Hubert Serve et al.   JOURNAL OF CLINICAL ONCOLOGY

Genomic Medicine Frontier in Human Solid Tumors: Prospects and Challenges

(2013) Rodrigo Dienstmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease

(2013) Kadoaki Ohashi et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations

(2013) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

(2013) Robert J Motzer et al.   LANCET ONCOLOGY

Effects of oncogenic mutations on the conformational free-energy landscape of EGFR kinase

(2013) L. Sutto et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cancer Genome Landscapes

(2013) B. Vogelstein et al.   SCIENCE

Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer

(2013) Rossana Berardi et al.   OncoTargets and Therapy

Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy

(2012) M. Takeda et al.   ANNALS OF ONCOLOGY

Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy

(2012) A. Awada et al.   ANNALS OF ONCOLOGY

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation

(2012) J. Cortes et al.   BLOOD

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

(2012) H. J. Khoury et al.   BLOOD

Landscape of EGFR signaling network in human cancers: Biology and therapeutic response in relation to receptor subcellular locations

(2012) Woody Han et al.   CANCER LETTERS

Combined EGFR/MET or EGFR/HSP90 Inhibition Is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET

(2012) L. Xu et al.   CANCER RESEARCH

Intratumor Heterogeneity: Evolution through Space and Time

(2012) C. Swanton   CANCER RESEARCH

Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence

(2012) Sai-Hong Ignatius Ou   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

New generation small-molecule inhibitors in myeloproliferative neoplasms

(2012) Francesco Passamonti et al.   CURRENT OPINION IN HEMATOLOGY

Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma

(2012) Madson Q. Almeida et al.   CURRENT OPINION IN ONCOLOGY

JAK2 inhibitors in the treatment of myeloproliferative neoplasms

(2012) Raoul Tibes et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

An update on dual Src/Abl inhibitors

(2012) Francesca Musumeci et al.   Future Medicinal Chemistry

Why imatinib remains an exception of cancer research

(2012) Steven D. Horne et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Risk of Rash in Cancer Patients Treated with Vandetanib: Systematic Review and Meta-Analysis

(2012) Alyx C. Rosen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial

(2012) Giorgio V. Scagliotti et al.   JOURNAL OF CLINICAL ONCOLOGY

Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial

(2012) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

(2012) Vincent A Miller et al.   LANCET ONCOLOGY

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Re-emergence of interferon-α in the treatment of chronic myeloid leukemia

(2012) M Talpaz et al.   LEUKEMIA

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

(2012) Jorge E. Cortes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study

(2011) H Joensuu et al.   BRITISH JOURNAL OF CANCER

Irreversible pan-ERBB inhibitor canertinib elicits anti-leukaemic effects and induces the regression of FLT3-ITD transformed cells in mice

(2011) Amanda Nordigården et al.   BRITISH JOURNAL OF HAEMATOLOGY

Basic and Therapeutic Aspects of Angiogenesis

(2011) Michael Potente et al.   CELL

New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer

(2011) G. R. Oxnard et al.   CLINICAL CANCER RESEARCH

A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor-Positive Breast Cancer

(2011) E. L. Mayer et al.   CLINICAL CANCER RESEARCH

Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors

(2011) J. C. Montero et al.   CLINICAL CANCER RESEARCH

Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: A meta-analysis of clinical trials

(2011) Fabio A.B. Schutz et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase

(2011) Gianantonio Rosti et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies

(2011) K. Podar et al.   CURRENT CANCER DRUG TARGETS

New JAK2 inhibitors for myeloproliferative neoplasms

(2011) Alfonso Quintás-Cardama et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Erratum

(2011) Mhd Yaser Al-Marrawi et al.   EXPERT OPINION ON PHARMACOTHERAPY

Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines

(2011) Kousaku Mimura et al.   INTERNATIONAL JOURNAL OF CANCER

Incidence and Risk of Congestive Heart Failure in Patients With Renal and Nonrenal Cell Carcinoma Treated With Sunitinib

(2011) Christopher J. Richards et al.   JOURNAL OF CLINICAL ONCOLOGY

Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR–ABL inhibitors as first-line therapy

(2011) P J Shami et al.   LEUKEMIA

Vascular endothelial growth factors and receptors: Anti-angiogenic therapy in the treatment of cancer

(2011) Sònia Tugues et al.   MOLECULAR ASPECTS OF MEDICINE

Current Status of Src Inhibitors in Solid Tumor Malignancies

(2011) L. N. Puls et al.   ONCOLOGIST

Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis

(2011) Annette K. Larsen et al.   PHARMACOLOGY & THERAPEUTICS

VEGF and angiopoietin signaling in tumor angiogenesis and metastasis

(2011) Pipsa Saharinen et al.   TRENDS IN MOLECULAR MEDICINE

Targeting Src family kinases in anti-cancer therapies: turning promise into triumph

(2011) Siyuan Zhang et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Angiogenesis Inhibitors: Current Strategies and Future Prospects

(2010) K. M. Cook et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Long-term outcomes in the second-line treatment of chronic myeloid leukemia

(2010) Elias Jabbour et al.   CANCER

Cell Signaling by Receptor Tyrosine Kinases

(2010) Mark A. Lemmon et al.   CELL

Targeting Multiple Kinase Pathways: A Change In Paradigm

(2010) L. Gossage et al.   CLINICAL CANCER RESEARCH

Randomized Phase III Trial of Gefitinib versus Docetaxel in Non-Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy

(2010) D. H. Lee et al.   CLINICAL CANCER RESEARCH

Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo

(2010) Z. A. Wainberg et al.   CLINICAL CANCER RESEARCH

Epidermal growth factor receptor inhibitors in oncology

(2010) Igor Vivanco et al.   CURRENT OPINION IN ONCOLOGY

Novel dual Src/Abl inhibitors for hematologic and solid malignancies

(2010) Silvia Schenone et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Phase I/II Study of the Src Inhibitor Dasatinib in Combination With Erlotinib in Advanced Non–Small-Cell Lung Cancer

(2010) Eric B. Haura et al.   JOURNAL OF CLINICAL ONCOLOGY

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

Mutations in ABL kinase domain are associated with inferior progression-free survival

(2010) Pratibha Sharma et al.   LEUKEMIA & LYMPHOMA

Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-α as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population

(2009) D. Castellano et al.   ANNALS OF ONCOLOGY

Sunitinib in solid tumors

(2009) Hui K Gan et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): Study of a comprehensive panel of molecular markers

(2009) Marcello Tiseo et al.   LUNG CANCER

Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis

(2008) Xiaolei Zhu et al.   ACTA ONCOLOGICA

Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib

(2008) Luis Paz-Ares et al.   Clinical & Translational Oncology

Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia

(2008) A. Quintas-Cardama et al.   CLINICAL CANCER RESEARCH